• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Data from Rebiotix’s Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016

PUNCH™CD2 Data Also to be Subject of Three Poster Presentations at ACG 2016


Download this press release (162 KB).

ROSEVILLE, MN (October 17, 2016) — Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that data from its Phase 2b, randomized, double-blind, placebo-controlled trial of RBX2660 as a possible prevention of recurrent  Clostridium difficile (C.diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2) will be presented at the United European Gastroenterology (UEG) Week 2016, to be held October 15-19 in Vienna, Austria.

The late-breaking oral presentation, “RBX2660, a microbiota-based drug for the prevention of recurrent Clostridium difficile infection, is safe and effective: results from a randomised, double-blinded, placebo-controlled trial,” (Abstract #LB08) will be presented by Robert Orenstein, D.O., an Associate Professor of Medicine and the Chair of the Division of Infectious Diseases at Mayo Clinic in Arizona, and study investigator on Monday, October 17, 2016, at 3:45-3:57 pm CET.

Additionally, data from the PUNCH™ CD2 clinical trial will be the subject of three poster presentations at American College of Gastroenterology (ACG) 2016 to be held October 14-19, 2016 in Las Vegas, Nevada:

  • “Does the Donor Matter? Results from PUNCH CD2: A Randomized Controlled Trial of a Microbiota-based Drug for Recurrent Clostridium difficile Infection,”
    Program Number P109, Sunday October 16, 2016, 3:30 – 7:00 pm, PT
  • “Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2 Trial,”
    Program Number P872, Monday, October 17, 2016, 10:30 am – 4:00 pm, PT
  • “Durable Prevention of Recurrent C. difficile Infection with RBX2660: Results of the PUNCH CD 2 Trial,” Program Number P1633, Tuesday, October 18, 2016, 10:30 am – 4:00 pm, PT

Lee Jones, co-founder, president and CEO, commented, “We are excited for the opportunity to have data from our Phase 2b clinical trial of RBX2660 presented at UEG Week 2016 and ACG 2016, two of the preeminent gastroenterology conferences in the world. Based on the results of the PUNCH™ CD2 study, our plan is to advance the clinical development of RBX2660 into a Phase 3 trial in recurrent C.diff. with the ultimate goal of bringing to market a drug product that addresses this critically important and potentially life-threatening disease.”


About Rebiotix Inc.

Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having successfully completed a Phase 2b randomized, double-blind, placebo controlled trial as a potential treatment for recurrent Clostridium difficile infection (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to treat recurrent C. diff. infection. Rebiotix’s development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:

Amy Wheeler
Tiberend Strategic Advisors
646-­362-­5750
awheeler@nulltiberend.com

Press Releases Press Releases

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT